Skip to main content

01.12.2017 | Case report | Ausgabe 1/2017 Open Access

BMC Cancer 1/2017

PD-L1 expressing circulating tumour cells in head and neck cancers

BMC Cancer > Ausgabe 1/2017
Arutha Kulasinghe, Chris Perry, Liz Kenny, Majid E. Warkiani, Colleen Nelson, Chamindie Punyadeera
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12885-017-3316-3) contains supplementary material, which is available to authorized users.
Bovine serum albumin
circulating tumour cells
epidermal growth factor recptor
Food and Drug Administration
Head and neck cancer
National Health and Medical Research Council
Overall Survival
Princess Alexandra Hospital
Phosphate buffered saline
Programmed cell death ligand
Programmed cell death ligand one
Progression free surivival
squamous cell carcinoma
University of Queensland


Head and neck cancer (HNC) patients often present with advanced metastatic disease. Whilst there have been improvements in the management of locoregional disease, distant metastatic spread remains a challenge in the field [ 13]. Palliative chemotherapy is platinum based and for patients who progress after first line treatment or are refractory, therapeutic options are limited. Numerous agents including cetuximab, paclitaxel, gemcitabine and docetaxel have been assessed prospectively in the treatment of platinum refractory patients and the time to progression ranged from 2 to 6 months [ 4]. These systemic treatments produce a significant degree of morbidity and new therapeutic options are therefore a need in these patients. Once there is an established role in metastatic disease, translation into the curative setting is appropriate.
The programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) pathway has shown to play a crucial role in tumour immune invasion. Recent literature suggests that PD-L1 over expression in solid tumour types has shown direct tumour protection. Recent studies have shown that antibodies targeting PD-1/PD-L1 have significant anti-tumour activity with a much lower toxicity profile and are currently being investigated in a number of tumour types [ 5, 6]. Pembrolizumab (previously MK-3475) is a highly selective, humanized igG4 (kappa) isotype monoclonal antibody designed to block PD-1 interacting with ligands, PD-L1 and PD-L2, thereby allowing the immune system to target and destroy the tumour. Pembrolizumab was the first anti PD-1 antibody to be approved by the FDA [ 6].
In the 2014, American Society of Clinical Oncology (ASCO) meeting, it was reported that in a majority (77.9%) of pre-treated HNSCC patients, PD-L1 is expressed in the tumour, defined by ≥1% stained cells in the tumour microenvironment [ 7]. In the Keynote 012 trial presented at ASCO 2015, tumour shrinkage was found in 57% of patients, and overall response of 24.8%, comprised of 26.3% in HPV-negative and 20.6% HPV-positive patients [ 5, 8]. The Keynote 012 study indicated that Pembrolizumab was twice as effective as cetuximab with durable responses in patients which has not been seen previously in HNC. Pembrolizumab was also well tolerated in these patients with low rates of adverse effects. 86% of the responsive patients enrolled in the Keynote 012 study continued to receive treatment highlighting the acceptable safety profile [ 7, 8].
Metastatic sites have shown unique genomic alterations, which can be quite different from the primary site [ 9, 10]. Invasive procedures are currently required to biopsy these metastatic sites, some of which may be inaccessible. Other studies have shown that these biopsies may not be representative of all of the metastatic disease [ 11]. An alternative approach used in other cancer types is the analysis of blood samples for circulating tumour cells (CTCs) as a form of “liquid biopsy” [ 1214]. These rare tumour cells in circulation represent the “transient” cancer cell population that have the propensity to metastasize to distant sites. Recent reports have shown how CTCs may provide complementary information to identify candidate therapeutic targets and drug resistance mechanisms [ 9, 12, 15]. Moreover, CTCs represent cells from the primary and metastatic sites, thereby possibly providing a more comprehensive overview of the tumour burden of an individual patient. CTCs in the blood of HNC patients provide an opportunity to identify patients “at-risk” of developing overt metastasis in due course. More importantly, the analysis of these metastatic seeds in circulation may reveal important information for systemic therapy targeting metastatic disease [ 9]. CTCs are currently being investigated as predictive biomarkers for HER-2 targeted therapies [ 16]. A similar strategy could be used for immune checkpoint blockade therapies such as PD-L1.
We report the case study of a 56 year old man who had been diagnosed with a supraglottic SCC and treated with chemoradiotherapy. The patient was assessed for CTCs by the FDA-approved CellSearch (Janssen Diagnostics) and spiral microfluidics platform. Single CTCs were detected by both platforms. Using the spiral approach, CTC clusters were identified expressing PD-L1. We propose the notion that CTC PD-L1 assessment may be an avenue to identify patients who would be suitable candidates for anti-PDL1 therapy.

Case presentation

A 56 year old Caucasian male with a background history of Crohn’s disease, treated with azathioprine, presented at the end of 2013 with a supraglottic T3N2b squamous cell carcinoma which was treated with upfront chemoradiotherapy, utilising Cisplatin. In October 2014, a CT scan showed a 20 mm right jugulodigastric node. Lung lesions were observed which were queried to be fungal/distant metastasis by the MDT clinic. Biopsied specimen of the lung lesions confirmed moderately differentiated SCC. Progressive disease to the lungs and pelvic bone were observed whilst on Taxol and Carboplatin, given weekly. Having limited options, a trial of infusional 5-FU (fluorouracil) was given at the end of 2015. The patient died in February 2016.

Chest X-ray

Nodules were projected over the left infrahilar region and within the right upper lobe suspicious for SCC metastasis (Fig. 1).

CTC assessment by CellSearch

The Patient presented with CellSearch-positive CTCs (2CTCs/7.5 ml) in circulation at time of presentation to clinic (Fig. 2).

CTC assessment by spiral technology

The Patient presented with 4 single CTCs (EGFR + CK + DAPI + CD45-) (Fig. 3) and 2 CTC clusters (EGFR + PDL1 + DAPI+) (Fig. 4). The CTC clusters showed a PD-L1 mean intensity in the mid to high dynamic range, determined using a panel of known HNC cell lines (Fig. 5).


The antibody against PD-L1 showed a relatively high mean intensity for (FaDu-Additional file 1: Fig. S1), medium (SCC25, CAL27), low (SCC15, 93-VU-147 T) and a negative control (K562 – Additional file 1: Fig. S2). PD-L1 staining of the CTC channel with spiked SCC-15 cells (Additional file 1: Fig. S3) and waste channel showing the bulk of leukocytes (Additional file 1: Fig. S4).

Isolation of CTCs by CellSearch

7.5 mL of whole blood collected in CellSave blood collection tubes (Janssen Diagnostics) was mixed with 6.5 ml of CellTracks™ buffer and centrifuged at 800 x g for 10 mins. The sample was placed on the AutoPrep™ system and the protocol followed as per manufacturer’s instructions. The system uses a positive selection enrichment based on EpCAM antibodies and characterizes the selected cells for pan-cytokeratin (pan-CK), CD45 and DAPI staining. A CTC was determined based on the following parameters: positive for EpCAM, pan-CK, DAPI, at least a diameter of 4x4μm and negative for CD45 (common leukocyte marker). The results were reported as the number of CTCs/7.5 ml whole blood.

Enrichment of CTCs by spiral microfluidics technology

8 mL of whole blood was collected in EDTA tubes (BD-Plymouth, UK). To reduce the cellular components passing through the spiral chip, a red blood cell (RBC) lysis was performed. Briefly, post RBC lysis (Astral Scientifix), the sample was centrifuged and the pellet resuspended in 10 mL of sheath buffer (1xPBS, 2 mM EDTA, 0.5% BSA). Tygon® tubing was inserted into the inlet/outlets of the spiral chip, and the inlet tubing connected to a syringe pump. The spiral chip was fixed into position on a phase contrast microscope (Olympus, IX71). The outlet tubing was connected to sterile 15 mL BD falcon collection tubes. To run the patient sample, the sample was carefully loaded into a 10 ml syringe and pumped through the spiral chip at a flow rate of 1.7 ml/min [ 17]. The outputs were collected and spun down at 300 x g for 5 mins. The enriched cell suspension was cytospun onto 2 glass slides using the Cytospin™ 4 Cytocentrifuge (ThermoScientific, USA). The presence of CTCs was determined by immunofluorescent staining.

Development of an immunoassay for PD-L1

Five head and neck cell lines were used to develop a dynamic range of PD-L1 expression. FaDu (ATCC®HTB43™), CAL27 (ATCC®CRL2095™), SCC25 (ATCC®CRL-1628™) were from the American Type Culture Collection (ATCC™). SCC15 (ATCC®CRL-1623™) a generous gift from Dr. Glen Boyle (QIMR, Brisbane) and 93-VU-147 T (CVCL_L895) (HPV-positive) cell line from Dr. Johan de Winter (VU Medical Center, Netherlands). The human chronic myelogenous leukemia K562 (ATCC®CCL-243) cells were used as a negative control (gift from Prof Maher Gandhi, UQDI, Brisbane). Briefly, cytospins (Cytospin™ Cytocentrifuge, USA) were prepared using aliquots of 1000 cells/slide by centrifugation at 300 x g for 5 mins. The slides were stained with PD-L1 as per the immunocytochemistry protocol below.


Briefly, the initial sample was stained using the CellSearch antibody cocktail (Janssen Diagnostics) and anti-EGFR antibody (AY13, Biolegend, San Diego) as previously described [ 1820]. A further slide was fixed with 4% formaldehyde for 10 mins, permeabilized with 0.2% Triton X-100 for 5 mins and blocked with 10% fetal-bovine serum in 0.1% PBS-Tween for 1 h at room temperature. The cells were incubated overnight at 4 °C with anti-EGFR antibody and anti-PD-L1 antibody [28-8] (Alexa Fluor® 647) (Abcam ab209960) 1/100 dilution. Nuclear DNA was visualized with DAPI. Rabbit IgG monoclonal isotype control (Alexa Fluor®647) (ab199093) was used to identify nonspecific binding. Cells were imaged on the Olympus IX3 inverted microscope.

Discussion and conclusions

The predictive value of PD-L1 expression in primary tissues is limited [ 9]. Furthermore, there is weak correlation between matched primary tumour and distant metastasis, suggesting that primary tumour is not an adequate surrogate for determining PD-L1 expression at metastatic sites [ 21]. Importantly, this highlights the fact that a single core biopsy may not suffice to determine tumour PD-L1 expression [ 9]. The FDA-approved CellSearch technology has shown clinical significance of EpCAM-positive CTCs [ 22]. However, there has been a shift in the field to maker-independent technologies to capture a greater proportion of CTCs in circulation in an unbiased fashion [ 18, 23]. By the use of established [ 9, 22] and spiral microfluidics technology [ 17, 24] this study aimed to capture the tumour cells in circulation of this patient and characterize the PD-L1 expression.
The patient presented with CTCs by enrichment using both CellSearch and spiral technologies. Importantly, the spiral technology was able to enrich for CTC clusters which are rarely detectable by CellSearch [ 25]. These microemboli/tumour cell clusters have shown an increased metastatic potential compared to single cells [ 26, 27]. Moreover, the cluster had a mid-high PD-L1 expression compared to the panel of known head and neck cancer cell lines. The PD-L1 + CTCs indicate that the patient had tumour cells in circulation with the capacity to block the immune system. These could be a potential targets for PD-L1 therapies [ 9]. The development of an immune-score is desirable for metastatic HNC patients.
In the 2016 AACR meeting, in locally advanced HNC patients, PD-L1+ CTCs were associated with shorter progression free survival (PFS) and overall survival (OS), and were proposed to “select and monitor patients for PD-1 checkpoint inhibitors” [ 28, 29]. These studies as well as this study, demonstrate that PD-L1 is expressed in HNSCC tumours and CTCs and may contribute to the tumours ability to evade the immune system. Moreover, that PD-L1 may be used as a biomarker for predicting responders from non-responders in lieu of the cost burden of such therapies.
This case report highlights the potential of using of CTCs to (i) identify patients ‘at-risk’ of developing metastasis (ii) identifying HNC patients that are likely to benefit from anti PD-L1 therapy and (iii) the development of a CTC PD-L1 immune-score for HNC. Further studies are warranted comparing patient tumour and CTC PD-L1 expression to develop predictive biomarkers.


The authors would like to thank Prof William B Coman (Brisbane, Australia) for clinical guidance, Dr. Mitesh Gandhi (Radiologist, Queensland Health, PAH), Ms. Dana Middleton (Clinical Trials Coordinator, PAH) and Dr. Christin Gasch for editorial assistance.


The study was supported by the Queensland Centre for Head and Neck funded by Atlantic Philanthropies and the Queensland Government in the design of the study. CP: QUT VC Fellowship. AK: QUT Postgraduate research scholarship.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

Study concept and design: AK, CN, CP, MEW. Acquisition of data: AK, CP1. Analysis and interpretation of data: AK, CN, CP, LK, CP1, MEW. Drafting of manuscript: AK, MEW, CP, LK. Critical revision: AK, MEW, CP1, CP, LK. CP1: Chris Perry, CP: Chamindie Punyadeera. All authors have read and approved and manuscript.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Written informed consent was obtained from the patient for publication.

Ethics approval and consent to participate

Ethics approval was obtained from the Metro South Health Service District Research Ethics committee in accordance with the NHMRC guidelines (HREC/12/QPAH/381) to collect bloods from the Princess Alexandra Hospital (PAH). The study had UQ ethics approval (2009000779). After written consent was obtained confirming that consent to publish has been obtained from the participant, 10 ml blood samples were obtained from the patient.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

BMC Cancer 1/2017 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.